Greenlee H et al., 2025-11-19: Phase I randomised, placebo-controlled crossover trial of CoQ10 with doxorubicin in breast cancer. CoQ10 at 300 mg/day raised serum levels without altering doxorubicin pharmacokinetics or causing adverse events; the trial closed early for slow accrual and tested no cardiac endpoint.
There were no clinically significant pharmacokinetic interactions between 300 mg/day CoQ10 and doxorubicin and no differences in TAC or adverse events during treatment and nontreatment periods.
Abstract, Results
Greenlee H et al., 2025-11-19: Phase I randomised, placebo-controlled crossover trial of CoQ10 with doxorubicin in breast cancer. CoQ10 at 300 mg/day raised serum levels without altering doxorubicin pharmacokinetics or causing adverse events; the trial closed early for slow accrual and tested no cardiac endpoint. Study type: randomized trial.
